

## Press Release

No. 6 / 6 February 2019

Page 1 / 3

# Gentle system for nasal oxygenation

## HI-Flow Star completes Dräger's noninvasive ventilation (NIV) portfolio

- Oxygen therapy with high flow rates
- Nasal cannula enhances comfort for patients
- Minimizes condensation thanks to breathable diaphragm

Lübeck – Dräger is incorporating adult high-flow oxygen therapy into its portfolio of non-invasive breathing support with the introduction of HI-Flow Star. This therapy has proven useful in hospitalized patients who require increased oxygenation because of impaired respiratory function. High-flow therapy is mainly used in patients with hypoxemic respiratory distress syndrome or myocardial infarction, in bronchoscopy, before intubation and after extubation. It is, in many cases, a supplement to mask-based non-invasive or invasive ventilation therapy. In the intensive care unit (ICU), sub-acute areas and surgical recovery rooms, patients recover faster after extubation, experience better outcomes and have a shorter length of stay with high-flow oxygen therapy compared with alternative oxygen delivery modalities.<sup>1,2</sup>

### Greater comfort for the patient

The HI-Flow Star nasal cannula reduces the risk of skin lesions on the face and gives the patient maximum freedom when eating, drinking and talking. The product can offer a more comfortable alternative to a noninvasive ventilation (NIV) face mask, particularly for patients with facial injuries. The symmetrical design of the nasal cannula allows it to be attached either from the left or right side of the patient's bed.

A heated breathing circuit supplies the previously warmed and humidified oxygen gas mixture to the patient. When warming and humidifying the air, there is often an accumulation of water in the connection hose of the nasal cannula.

### Contact

Corporate Communications:  
Melanie Kamann  
Tel +49 451 882-3998  
melanie.kamann@draeger.com

Investor Relations:  
Thomas Fischler  
Tel +49 451 882-2685  
thomas.fischler@draeger.com

Drägerwerk AG & Co. KGaA  
Moislinger Allee 53-55  
23558 Lübeck, Germany  
www.draeger.com

<sup>1</sup> Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome, Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, Montini L, De Gaetano A, Navalesi P, Antonelli M., Am J Respir Crit Care Med. 2014 Aug 1;190(3):282-8. doi: 10.1164/rccm.201402-0364OC.

<sup>2</sup> Can high-flow nasal cannula reduce the rate of reintubation in adult patients after extubation? A meta-analysis, BMC Pulm Med. 2017; 17: 142. Yue-Nan Ni, Jian Luo, He Yu, Dan Liu, Bin-Miao Liang, Rong Yao, and Zong-An Liang

## Press Release

No. 6 / 6 February 2019

Page 2 / 3

The flexible, breathable diaphragm of the HI-Flow Star nasal cannula minimizes condensation inside, which also increases comfort for the patient. As a disposable item, it reduces the risk of cross-contamination during daily clinical use.

### Dräger offers complete system

HI-Flow Star completes Dräger's portfolio of accessories for non-invasive breathing support, which already extends from full-face masks to low-flow oxygen systems. Available in three sizes, the HI-Flow Star system can be used with a gas mixer, such as Dräger's Oxy mixer, and with Dräger's Savina 300 and Evita V intensive care ventilators, all of which have an O2 therapy function.

The HI-Flow Star system is manufactured by Drägerwerk AG & Co. KGaA.

### Dräger. Technology for Life®

Dräger is an international leader in the fields of medical and safety technology. Our products protect, support and save lives. Founded in 1889, Dräger generated revenues of around EUR 2.6 billion in 2017. The Dräger Group is currently present in more than 190 countries and has more than 13,000 employees worldwide. Please visit [www.draeger.com](http://www.draeger.com) for more information.

### Images:



### Contact

Corporate Communications:  
Melanie Kamann  
Tel +49 451 882-3998  
[melanie.kamann@draeger.com](mailto:melanie.kamann@draeger.com)

Investor Relations:  
Thomas Fischler  
Tel +49 451 882-2685  
[thomas.fischler@draeger.com](mailto:thomas.fischler@draeger.com)


Drägerwerk AG & Co. KGaA  
Moislinger Allee 53-55  
23558 Lübeck, Germany  
[www.draeger.com](http://www.draeger.com)

[www.twitter.com/DraegerNews](https://twitter.com/DraegerNews)  
[www.facebook.com/DraegerGlobal](https://www.facebook.com/DraegerGlobal)  
[www.youtube.com/Draeger](https://www.youtube.com/Draeger)

## Press Release

No. 6 / 6 February 2019

Page 3 / 3



Please visit our Press Center for further information and pictures:

[https://www.draeger.com/de\\_corp/Presse](https://www.draeger.com/de_corp/Presse)

Note: The product mentioned in this press release will not initially be available in all countries. For more information on availability in countries other than Germany, please visit the website for your country or contact the local Dräger Sales organization.

### Contact

Corporate Communications:  
Melanie Kamann  
Tel +49 451 882-3998  
[melanie.kamann@draeger.com](mailto:melanie.kamann@draeger.com)

Investor Relations:  
Thomas Fischler  
Tel +49 451 882-2685  
[thomas.fischler@draeger.com](mailto:thomas.fischler@draeger.com)

Drägerwerk AG & Co. KGaA  
Moislinger Allee 53-55  
23558 Lübeck, Germany  
[www.draeger.com](http://www.draeger.com)

[www.twitter.com/DraegerNews](https://www.twitter.com/DraegerNews)  
[www.facebook.com/DraegerGlobal](https://www.facebook.com/DraegerGlobal)  
[www.youtube.com/Draeger](https://www.youtube.com/Draeger)